ULISES
Financiado
Immunological incompatibility as a basis for cancer curing and vaccination
In the ULISES project, we aim at developing an immunologic-based treatment strategy where cancer cells are reprogrammed to become visible to the patient’s own immune system, which will see them as not belonging to the body and wil...
In the ULISES project, we aim at developing an immunologic-based treatment strategy where cancer cells are reprogrammed to become visible to the patient’s own immune system, which will see them as not belonging to the body and will attack them, emulating the allogenic response to incompatible transplants. Thus, it will constitute a natural treatment, as the patient’s own immune system will be used to attack cancer cells, with no drugs, chemotherapy, radiotherapy, transplants, etc., significantly reducing the treatment time to few weeks and producing minimal or almost null side effects. In addition, this reprogramming will lead to an immunological-memory avoiding future relapses (vaccine-like effect) through TIL (Tumour Infiltrating Lymphocytes) generated around the tumour microenvironment by the immune system.
Porous nanoparticles (NPs) will be used as carriers for delivering a plasmid DNA cargo into the tumour cells in order to produce that reprogramming. These NPs will specifically recognize the cancer cells through the CD47 protein and the folate receptors beta and alpha, highly expressed on the surface of the cells. Moreover, two messenger RNAs will be used in order to avoid the side effects caused by targeting CD47 protein (mainly anaemia, neutropenia and thrombocytopenia).
Finally, highlight that the ULISES therapeutic strategy will be a global treatment, since only with 3 subtypes of NP (one for each chosen alloHLA-A), we will be able to target the entire population for each cancer type. For the implementation and validation of this strategy, we will focus on pancreatic cancer because of its high aggressiveness, lack of effective treatments and little life expectancy, but the developed strategy will also be valid for other cancer varieties with minimal modifications.
ver más
Duración del proyecto: 48 meses
Fecha Inicio: 2020-06-18
Fecha Fin: 2024-06-30
Fecha Fin: 2024-06-30
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2024-06-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
FETOPEN-01-2018-2019-2020:
FET-Open Challenging Current Thinking
Cerrada
hace 6 años
Presupuesto
El presupuesto total del proyecto asciende a
3M€
Líder del proyecto
FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
650K
Perfil tecnológico
TRL
4-5
650K
311.67K€ |
Participante